Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.74 |
| ▸ | CA2 | P00918 | 16/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941311 | 0.92 | CA2 (0.64) | CA1CA2OPRM1OPRD1KDM4E | |
| SCHEMBL31670533 | 0.92 | CA2 (0.75) | CA1CA2OPRM1OPRD1CA12 | |
| SCHEMBL13687209 | 0.89 | CA1 (0.72) | CA1CA2OPRM1OPRD1 | |
| SCHEMBL31670539 | 0.87 | CA1 (0.76) | CA1CA2OPRM1OPRD1CA12 | |
| SCHEMBL31670540 | 0.86 | CA1 (0.70) | CA1CA2OPRM1OPRD1CA12 | |
| SCHEMBL31670546 | 0.85 | CA1 (0.77) | CA1CA2OPRM1OPRD1CA12 | |
| SCHEMBL11412620 | 0.83 | CA1 (0.56) | CA1CA2OPRM1OPRD1KMT2A | |
| SCHEMBL1272484 | 0.82 | CA1 (0.71) | CA1CA2 | |
| SCHEMBL13687260 | 0.81 | CA1 (0.66) | CA1CA2KDM4ELMNAGLA | |
| SCHEMBL13753103 | 0.81 | HPGD (0.73) | KDM4EKMT2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | CA1 1096/4885CA2 420/4885OPRM1 32/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | CA1 1096/4885CA2 420/4885OPRM1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.